J Endod:使用GentleWave系统治疗的术后疼痛分析:一项随机对照试验

2020-07-03 lishiting MedSci原创

标准的冲洗治疗通常使用常规的针头以及一定频率的声波激活。GentleWave系统结合了冲洗液输送和声波激活。这篇临床随机试验的目的是为了评估GWS系统是否会显著减少术后疼痛的发生率和强度。

根管清理和预备是促使冲洗液和药物达到根尖1/3的必要之举。标准的冲洗治疗通常使用常规的针头以及一定频率的声波激活。GentleWave系统(GWS; Sonendo, Inc, Laguna Hills, CA)结合了冲洗液输送和声波激活。这篇临床随机试验的目的是为了评估GWS系统是否会显著减少术后疼痛的发生率和强度。

研究使用数字评估量表记录患者术前6小时的疼痛水平。所有的受试者随机分为2组并且不知道其接受的治疗方法。标准(control)组采用牙髓治疗以及常规的侧方开口针头冲洗和超声激活。第二组采用牙髓治疗和GWS。治疗后,采用数字评估量表记录术后6, 24, 72和168小时的疼痛水平。

结果显示,在标准治疗组中,72.2%的患者至少经历了1次术后疼痛,而在GWS组,83.3%的患者至少经历了1次术后疼痛。2种治疗后发生的最高疼痛强度水平均发生在术后6小时。所有疼痛在术后6小时随着时间的延长而减弱(P < 1.237e-7)。

结论:各治疗组术后疼痛的强度或发生率之间无显著性差异。然而,2组均显示疼痛随着时间的延长而明显减弱。

原始出处

Daryl Grigsby Jr, Ronald Ordinola-Zapata, et al. Postoperative Pain After Treatment Using the GentleWave System: A Randomized Controlled Trial. J Endod., 2020 Jun 14;S0099-2399(20)30266-1. doi: 10.1016/j.joen.2020.04.004.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775512, encodeId=cdfb1e75512a8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Aug 19 13:39:47 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987270, encodeId=20bc198e270ed, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Dec 27 02:39:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296245, encodeId=7d371296245ce, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587670, encodeId=30b7158e67054, content=<a href='/topic/show?id=1e6ae95729' target=_blank style='color:#2F92EE;'>#GentleWave#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7957, encryptionId=1e6ae95729, topicName=GentleWave)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74bf17545187, createdName=stfoxst, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614003, encodeId=f0d51614003c6, content=<a href='/topic/show?id=da23e693982' target=_blank style='color:#2F92EE;'>#系统治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76939, encryptionId=da23e693982, topicName=系统治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69d419466610, createdName=12498717m72(暂无昵称), createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038938, encodeId=81dc10389382d, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Fri Jul 03 22:39:47 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
    2020-08-19 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775512, encodeId=cdfb1e75512a8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Aug 19 13:39:47 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987270, encodeId=20bc198e270ed, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Dec 27 02:39:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296245, encodeId=7d371296245ce, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587670, encodeId=30b7158e67054, content=<a href='/topic/show?id=1e6ae95729' target=_blank style='color:#2F92EE;'>#GentleWave#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7957, encryptionId=1e6ae95729, topicName=GentleWave)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74bf17545187, createdName=stfoxst, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614003, encodeId=f0d51614003c6, content=<a href='/topic/show?id=da23e693982' target=_blank style='color:#2F92EE;'>#系统治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76939, encryptionId=da23e693982, topicName=系统治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69d419466610, createdName=12498717m72(暂无昵称), createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038938, encodeId=81dc10389382d, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Fri Jul 03 22:39:47 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775512, encodeId=cdfb1e75512a8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Aug 19 13:39:47 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987270, encodeId=20bc198e270ed, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Dec 27 02:39:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296245, encodeId=7d371296245ce, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587670, encodeId=30b7158e67054, content=<a href='/topic/show?id=1e6ae95729' target=_blank style='color:#2F92EE;'>#GentleWave#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7957, encryptionId=1e6ae95729, topicName=GentleWave)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74bf17545187, createdName=stfoxst, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614003, encodeId=f0d51614003c6, content=<a href='/topic/show?id=da23e693982' target=_blank style='color:#2F92EE;'>#系统治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76939, encryptionId=da23e693982, topicName=系统治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69d419466610, createdName=12498717m72(暂无昵称), createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038938, encodeId=81dc10389382d, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Fri Jul 03 22:39:47 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775512, encodeId=cdfb1e75512a8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Aug 19 13:39:47 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987270, encodeId=20bc198e270ed, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Dec 27 02:39:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296245, encodeId=7d371296245ce, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587670, encodeId=30b7158e67054, content=<a href='/topic/show?id=1e6ae95729' target=_blank style='color:#2F92EE;'>#GentleWave#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7957, encryptionId=1e6ae95729, topicName=GentleWave)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74bf17545187, createdName=stfoxst, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614003, encodeId=f0d51614003c6, content=<a href='/topic/show?id=da23e693982' target=_blank style='color:#2F92EE;'>#系统治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76939, encryptionId=da23e693982, topicName=系统治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69d419466610, createdName=12498717m72(暂无昵称), createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038938, encodeId=81dc10389382d, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Fri Jul 03 22:39:47 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1775512, encodeId=cdfb1e75512a8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Aug 19 13:39:47 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987270, encodeId=20bc198e270ed, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Dec 27 02:39:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296245, encodeId=7d371296245ce, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587670, encodeId=30b7158e67054, content=<a href='/topic/show?id=1e6ae95729' target=_blank style='color:#2F92EE;'>#GentleWave#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7957, encryptionId=1e6ae95729, topicName=GentleWave)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74bf17545187, createdName=stfoxst, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614003, encodeId=f0d51614003c6, content=<a href='/topic/show?id=da23e693982' target=_blank style='color:#2F92EE;'>#系统治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76939, encryptionId=da23e693982, topicName=系统治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69d419466610, createdName=12498717m72(暂无昵称), createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038938, encodeId=81dc10389382d, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Fri Jul 03 22:39:47 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1775512, encodeId=cdfb1e75512a8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Aug 19 13:39:47 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987270, encodeId=20bc198e270ed, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Dec 27 02:39:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296245, encodeId=7d371296245ce, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587670, encodeId=30b7158e67054, content=<a href='/topic/show?id=1e6ae95729' target=_blank style='color:#2F92EE;'>#GentleWave#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7957, encryptionId=1e6ae95729, topicName=GentleWave)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74bf17545187, createdName=stfoxst, createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614003, encodeId=f0d51614003c6, content=<a href='/topic/show?id=da23e693982' target=_blank style='color:#2F92EE;'>#系统治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76939, encryptionId=da23e693982, topicName=系统治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69d419466610, createdName=12498717m72(暂无昵称), createdTime=Sun Jul 05 10:39:47 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038938, encodeId=81dc10389382d, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Fri Jul 03 22:39:47 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
    2020-07-03 肿瘤克星

    高质量研究,读起来真爽,谢谢梅斯

    0

相关资讯

J Endod:机械辅助震荡减轻根管治疗的术后疼痛:一项系统性回顾和对随机临床试验的Meta分析

这篇系统性回顾和Meta分析的目的是为了评估机械辅助震荡与针头注射冲洗相比是否能够减轻成年患者根管治疗后的术后疼痛(PP)。

J Endod:粘膜下注射皮质类固醇对不可逆牙髓炎根管治疗后疼痛及生活质量的影响:一项随机临床试验

这篇调查研究的目的是为了评估局部浸润皮质类固醇对不可逆牙髓炎行一次性牙髓治疗后牙齿疼痛及生活治疗(QOL)的影响。

J Endod:患者根管治疗后持续疼痛的3年疗效观察分析

这篇研究的目的是为了评估患者根管治疗(RCT)后6个月存在持续疼痛的长期疗效,并评估不同患者疼痛迁延的特点。

J Endod:术前双氯酚酸钾对有症状不可逆牙髓炎下颌磨牙术后疼痛的影响

这篇预期随机双盲临床试验的目的是为了评估术前单独使用口服剂量的双氯酚酸钾(DFK)对罹患有症状不可逆牙髓炎(SIP)下颌磨牙的患者术后疼痛以及急救镇痛药摄入的影响。

2019 SFAR指南:术后疼痛管理

2019年2月,法国麻醉和重症医学学会(SFAR)更新发布了术后疼痛管理指南,该指南时对2008年版指南的更新,指南主要内容涉及围术期疼痛评估,镇痛检查,术后疼痛药物治疗和术后局部镇痛。

Anesthesiology:围手术期使用普瑞巴林和氯胺酮可预防心脏手术后的持续性疼痛

手术后的持续性疼痛十分常见,影响患者的生活质量。本研究假设使用前加巴林和氯胺酮可以预防心脏手术后的持续性疼痛。